Tassone Giusy, Mazzorana Marco, Pozzi Cecilia
Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018-2022, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.
Diamond Light Source Ltd., Diamond House, Harwell Science & Innovation Campus, Didcot OX11 0DE, UK.
Pharmaceuticals (Basel). 2022 Oct 29;15(11):1341. doi: 10.3390/ph15111341.
Protozoan parasites are responsible for several harmful and widespread human diseases that cause high morbidity and mortality. Currently available treatments have serious limitations due to poor efficiency, strong adverse effects, and high cost. Hence, the identification of new targets and the development of specific drug therapies against parasitic diseases are urgent needs. Heat shock protein 90 (HSP90) is an ATP-dependent molecular chaperone that plays a key role in parasite survival during the various differentiation stages, spread over the vector insect and the human host, which they undergo during their life cycle. The N-terminal domain (NTD) of HSP90, containing the main determinants for ATPase activity, represents the most druggable domain for inhibitor targeting. The molecules investigated on parasite HSP90 are mainly developed from known inhibitors of the human counterpart, and they have strong limitations due to selectivity issues, accounting for the high conservation of the ATP-binding site between the parasite and human proteins. The current review highlights the recent structural progress made to support the rational design of new molecules able to effectively block the chaperone activity of parasite HSP90.
原生动物寄生虫导致了几种有害且广泛传播的人类疾病,这些疾病会引发高发病率和高死亡率。目前可用的治疗方法存在严重局限性,原因包括效率低下、副作用强烈以及成本高昂。因此,识别新的靶点并开发针对寄生虫疾病的特异性药物疗法是迫切需求。热休克蛋白90(HSP90)是一种依赖ATP的分子伴侣,在寄生虫生命周期中经历的不同分化阶段、在媒介昆虫和人类宿主中的传播过程中,对寄生虫的存活起着关键作用。HSP90的N端结构域(NTD)包含ATP酶活性的主要决定因素,是抑制剂靶向的最具药物可及性的结构域。针对寄生虫HSP90研究的分子主要是基于人类HSP90的已知抑制剂开发的,由于选择性问题,它们存在很大局限性,这是因为寄生虫和人类蛋白质之间ATP结合位点具有高度保守性。本综述重点介绍了近期在支持合理设计能够有效阻断寄生虫HSP90伴侣活性的新分子方面取得的结构进展。